26th Nov 2019 10:42
26 November 2019
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Issue of Equity
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that Martin Whitaker, Chief Executive Officer, exercised an option to acquire 80,000 ordinary shares of £0.05 each ("New Ordinary Shares"). The options were granted under the Diurnal Group plc Long Term Incentive Plan ("Plan") and vested on 8 November 2019, as announced on the same date. The exercise price payable is 5p pence per Ordinary Share.
Following the transactions, the total beneficial interest of Martin Whitaker and his connected parties is 394,991 Ordinary Shares, representing 0.46% of the total voting rights.
Application has been made for admission of the 80,000 New Ordinary Shares issued under the Plan to trading on AIM, which is anticipated to occur at 8:00am on Monday 2 December 2019 ("Admission"). The New Ordinary Shares will rank pari passu with the existing shares of common stock of the Company. Following Admission, the Company's issued ordinary share capital will consist of 86,505,440 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights in Diurnal following Admission will be 86,505,440.
The above figure of 86,505,440 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Details of the full notifications received by the Company are set out below:
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Martin Whitaker | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Executive Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Exercise of share options
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
Exercise 5p | 80,000 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price | |||||
e)
| Date of the transaction
| 25 November 2019 | |||
f)
| Place of the transaction
| XLON | |||
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
Related Shares:
DNL.L